The Centers for Medicare & Medicaid Services announced a $50 billion Rural Health Transformation Program, awarding funding to all 50 states beginning in 2026. This signals a meaningful shift in how care may be delivered, reviewed, and evaluated in rural markets.

CMS is testing a negotiated-pricing approach to expand access to GLP-1 therapies through the BALANCE Model, beginning as early as May 2026 in Medicaid and January 2027 in Medicare Part D. A transitional Medicare payment demonstration starting July 2026 will provide short-term access at a predefined cost-sharing level.

The rule refines the existing transparency framework by focusing on usability through simplified files and harmonized consumer disclosures. Organizations have until February 21, 2026 to comment on operational and technical details that could shape the final requirements.

The expansion of MFN pricing agreements marks a significant federal intervention into prescription drug pricing, combining Medicaid access, direct-to-consumer purchasing, and domestic manufacturing incentives. While immediate impacts will be most pronounced within Medicaid programs and for the specific drugs named, the broader policy signal may influence payer strategy, pricing negotiations, and regulatory expectations moving into 2026.

CMS is testing whether international reference pricing can be operationalized within Medicare Part B without degrading access or quality. If finalized, the GLOBE Model would become one of the most consequential mandatory drug pricing demonstrations implemented to date.